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CONTEXT: Kisspeptin is a recently identified hormone encoded by theKISS1 gene, playing a critical
role in human reproduction. Plasma kisspeptin levels rise dramatically during normal pregnancy
due to placental synthesis, which implicates it as a potential tool for assessing risks of pregnancy
complications. No previous prospective study has investigated the association between plasma
kisspeptin and risk of miscarriage.
OBJECTIVE:Todeterminewhethera singleplasmakisspeptinor serumhCGmeasurement inasymp-
tomatic women attending their booking antenatal visit are associated with miscarriage.
DESIGN: Prospective cohort study
SETTING: Tertiary obstetric centre
PARTICIPANTS: 993 asymptomatic pregnant women 6weeks gestation attending routine ante-
natal booking visit were recruited between January 2010 and December 2012.
MAIN OUTCOME MEASURES: Plasma kisspeptin and serum hCG were measured during antenatal
booking visit. Pregnancy outcome was recorded prospectively.
RESULTS: Plasma kisspeptin correlated with gestation (r20.57; P0.0001). Gestational age-cor-
rected (multiples of median, MoM) plasma kisspeptin was 60.4% lower (P0.001), and MoM-hCG
was 36.1% lower (P0.001) in women later diagnosed with miscarriage compared with women
without miscarriage. Increased plasma kisspeptin was associated with reduced miscarriage risk,
even after adjusting for age, BMI, gestational age, smoking and blood pressure (OR 0.13 [0.08–
0.22], P0.0001). Kisspeptin had a higher diagnostic performance for miscarriage than hCG (ROC-
AUC: 0.8990.025, plasma kisspeptin; 0.7750.040, serum hCG, P0.01 vs. plasma kisspeptin).
CONCLUSION: Our data suggest for the first time that a single plasma kisspeptin measurement
taken during the antenatal booking visit provides a potential novel marker for identifying asymp-
tomatic pregnant women 6weeks gestation at increased risk of miscarriage.
Miscarriage is defined as spontaneous pregnancy lossprior to 24weeks of gestation (1). Ten to twenty percent of all clinically recognized pregnancies end inmis-carriage (2, 3).Womenaffectedbya singlemiscarriage not
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only suffer devastating emotional consequences (4), but
are also at increased risk of developing serious antenatal
morbidities such as preeclampsia and preterm delivery
during subsequent pregnancies (5–7). Prior to 6weeks ges-
tation, most miscarriages result from cytogenetic abnor-
malities in the embryo such as chromosomal trisomy (8).
However later during gestation, other causes of miscar-
riage, such as placental insufficiency, intrauterine infec-
tion and thrombosis, become more common. There are
currently no proven treatments to prevent noncytogenetic
causes of miscarriage; however this may reflect that there
is currently no established marker to identify women at
increased risk of miscarriage. Fetal viability may be esti-
mated using serial measurement of serum hCG during
multiple hospital visits; however approximately 20% of
cases resulting in miscarriage are also associated with ris-
ing levels of serum hCG which are typical of viable preg-
nancy and the clinical utility is limited (9). There is there-
fore both a delay and a high degree of uncertainty in
diagnosing miscarriage using this approach, which can be
a source of further distress for affected couples.
Abnormal placentation (placental development) is
found in two-thirds of cases of miscarriage (10, 11). The
recently identified hormone kisspeptin has been suggested
to play an important regulatory role in placentation. Kiss-
peptin consists of a group of arginine-phenylalanine (RF)
amide peptides encoded by the KISS1 gene which bind to
the kisspeptin receptor (12–15). Kisspeptin is expressed
most abundantly in the syncytiotrophoblast cells of the
placenta, where it may regulate invasion into thematernal
uterine wall (14, 16, 17). Kisspeptin is also expressed in
areas of the brain such as hypothalamus, amygdala and
caudate nucleus, in addition to the pituitary, pancreas,
adipose, testis, lymphocytes and spleen (13, 15). Circu-
lating levels of kisspeptin increase gradually during preg-
nancy, becoming markedly elevated up to 7000-fold dur-
ing later pregnancy when compared with nonpregnant
women (18). Recent case-control studies have suggested
that circulating kisspeptin levels are reduced in women
with pre-eclampsia and intra-uterine growth retardation
(IUGR),when comparedwith uncomplicated pregnancies
(19, 20). Levels of placental kisspeptin expression are sig-
nificantly lower in women with recurrent miscarriage
when compared with placental tissue in electively termi-
nated pregnancies (21). This preliminary evidence there-
fore suggests that low placental kisspeptin levels may be
associated with increased risk of miscarriage or other se-
rious obstetric complications if the fetus survives. It is cur-
rently not knownwhether plasma kisspeptin levels during
pregnancy are associated with miscarriage.
We conducted a prospective cohort study including
over 900 women at a single obstetric center, to determine
whether levels of plasma kisspeptin or serum hCG are
associated with miscarriage in asymptomatic women 
6weeks gestation attending their booking antenatal visit.
Materials and Methods
This study was performed in accordance with the Decla-
ration of Helsinki following ethical approval (West Lon-
don Research Ethics Committee; Q0406/80). Women at-
tending routine antenatal booking visit at Queen
Charlotte’s and Chelsea Hospital London, UK were in-
vited to participate between January 2010 and December
2012. Nine hundred and ninety-three pregnant women
attending their routine antenatal booking clinic appoint-
mentwere recruited. Followingwritten informed consent,
a single blood sample was taken for measurement of
plasma kisspeptin and serum hCG. Women with renal
failure were excluded due to assay interference with kiss-
peptin measurement. Emergency admissions or cases of
suspected miscarriage were excluded. Twelve women
were lost to follow-up, despite attempts of obstetric staff
to contact these women. The remaining 981 women were
followed-up until the outcome of pregnancy was known.
Patient details and outcomes:
All pregnancies were dated according to a dating ultrasound
scan (typically at 8–14weeks gestation) performed in the ante-
natal clinic.Ultrasoundparameters froma20week fetal anomaly
scan, patient-held clinical notes, and hospital electronic records
were collated to establish whether miscarriage or live birth had
occurred. Miscarriage was either diagnosed using ultrasound
scanning, or was self-reported. Patient details are summarized in
Table 1.
Measurement of plasma kisspeptin
immunoreactivity
Measurement of plasma kisspeptin immunoreactivity (IR)
was performedusing an established in-house radioimmunoassay
(RIA) previously developed in our laboratory (22, 23). In brief,
a known quantity of I-125 labeled kisspeptin-54 peptide is used
to compete with an unknown quantity of kisspeptin for binding
to a limited quantity of antibody derived from sheep antiserum
raised against kisspeptin. Radioactivity of charcoal-separated
antibody-peptide complexes is inversely proportional to levels of
kisspeptin in the sample. The antibody cross-reacted 100%with
human kisspeptin-54, kisspeptin-14, and kisspeptin-10 and less
than 001%with other relatedRF amide proteins, including pro-
lactin-releasing peptide, RF amide-related peptide (RFRP) 1,
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RFRP2, RFRP3, QRFP43, neuropeptide FF, and neuropeptide
AF. The limit of detectability was 2 pmol/L, and the intra- and
interassay coefficients of variation were 83 and 102%,
respectively.
Measurement of total hCG immunoreactivity
Measurement of plasma hCG was performed using the Sie-
mens Immulite 2000 total immunometric hCG assay run on
board the Siemens Immulite 2000 instrument (Siemens Health-
care Diagnostics 1717 Deerfield Road, Deerfield, IL, USA). Ac-
cording to the manufacturer’s kit insert the analytical sensitivity
of the assay is 0.4 IU/L. Performance is monitored daily and
internal quality control (QC) samples ranging 5–250 IU/L yield
intra- and interassay coefficients of variation (CV) of less than
10%. Studies using the latest WHO standard preparations for
common hCG protein variants have demonstrated that the Im-
mulite 2000 assay detects all hCG isoforms, but is associated
with relative slight overestimation of hCG and underdetection
of the hCG core fragment isoforms (24, 25).
Data Analysis and Statistics:
Sample size aimed to recruit sufficient cases to determine the
association of plasmakisspeptinwithmiscarriage, correcting for
confounding variables that may confer an increased risk of mis-
carriage (ie, participant age, gestational age, body mass index
(BMI) [BMI], smoking, diastolic blood pressure (BP), and sys-
tolic BP). Data was analyzed using Prism 5 (GraphPad, Califor-
nia). In order to account for variation in circulating kisspeptin
and hCG levels during pregnancy, we calculated multiple of me-
dian (MoM) levels of each hormone measurement during the
gestation when blood was collected. Data are presented as
meanstandard deviation (s.d.). Pairs of means were analyzed
using the unpaired two-tailed t test. Multiple means were com-
pared using one-way ANOVA with Tukey’s Multiple Compar-
ison Test. Logistic regression was used to analyze associations
betweenplasmakisspeptin andhCGwith risk ofmiscarriage; the
rationale for log transformation was to reduce the variability in
kisspeptin levels (particularly at high levels), in order to better
study the association with risk of miscarriage. P .05 was con-
sidered statistically significant.
Results
Baseline characteristics of pregnant subjects
attending their antenatal booking visit
Nine hundred and ninety-three women attending an-
tenatal clinic for a routine booking antenatal appointment
were recruited to the study. Twelve women (ie, 1% of the
sample) were lost to follow-up, so their datawas excluded
from all analyses. The remaining 981 women had a mean
gestation of 11.2weeks (range 5.9–22.1) (see Table 1 for
characteristics). Thirty-two pregnancies were multiple
(thirty twin pregnancies of which six were monochori-
onic; two triplet pregnancies). No participants were at-
tending as an emergency, or presented with symptoms of
threatened miscarriage such as abdominal pain or vaginal
bleeding.
Distribution of plasma levels of kisspeptin in
pregnant women at the antenatal booking visit
with a singleton pregnancy not resulting in
miscarriage
In single pregnancies not resulting inmiscarriage, levels
of plasma kisspeptin increased steadily during each week
of gestation during the first trimester of pregnancy (Figure
1A). Plasma kisspeptin in single pregnancies was highly
significantly and positively correlatedwith the gestational
week of pregnancy (r  0.57; P  .0001) (Figure 1B).
Serum hCG in single pregnancies had a complex relation-
ship with gestational age; levels peaked around the eighth
gestational week, before reducing with increasing gesta-
tional week. (Figure 1C-D). Log transformation of serum
hCG in single pregnancies suggested a significant and neg-
ative correlation with gestational age (r-0.41, 95% CI
–0.47 to –0.36) (data not shown).
In singleton pregnancies not resulting in miscarriage,
MoMplasmakisspeptin levelswere classifiedaccording to
duration of sample storage at –20°C prior to kisspeptin
Table 1. Clinical characteristics of study participants
N
number
Mean Age (years)
(SD)
Mean BMI
(kg/m2)
(SD)
Mean Parity
(SD)
Mean Gestation
(weeks)
(SD)
%
Smoking
during
pregnancy
Mean Systolic
BP (mmHg)
Mean
Diastolic BP
(mmHg)
Total number of women
participating in study
981 32.6 (2.0) 24.8 (5.5) 0.6 (0.8) 11.2 (2.0) 4.0% 107.9
(17)
65.5
(8.8)
Number of women with
singleton pregnancy
without miscarriage
899 32.4 (5.1) 24.7 (5.4) 0.7 (0.8) 11.3 (1.9) 4.0% 107.8
(17.2)
65.5
(8.9)
Number of women with
singleton miscarriage
50 33.1 (4.8) 26.3 (7.4) 0.6 (0.8) 9.8 (3.1) 6.2% 108.2
(12.7)
65.6
(8.4)
Number of women with
multiple pregnancy
32 35.5 25.9 0.5 10.7 3.4% 109.9
(12.9)
68.1
(8.5)
(5.6) (5.6) (0.9) (1.5)
Ethnicity
(981)
Caucasian 574 (58.5%)
South Asian 121 (12.3%)
Afrocaribbean 107 (10.9%)
Other 109 (11.1%)
Mixed 24 (2.4%)
Unknown 46 (4.7%)
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measurement (between 10 and 31 months; Supplemental
Figure 2). No significant differences between MoM kiss-
peptin levels among any group were observed (P  .07).
Relationship between plasma kisspeptin and
miscarriage in singleton pregnancies
Fifty of the 981 (5.1%) women attending antenatal
clinic with a singleton pregnancy were diagnosed with
miscarriage after recruitment to the study (Supplemental
Table 1). Multiples of Median (MoM; gestation-cor-
rected) kisspeptin levels were 60% lower in women with
a singleton pregnancy who later experienced miscarriage
when compared with unaffected pregnancies (MoM kiss-
peptin: 1.06  0.42, singleton-no-miscarriage, 0.42 
0.39, singleton-with-miscarriage, P  .001 vs. singleton-
no-miscarriage) (Figure 2A). By comparison, MoM hCG
levels were only 36% lower in singleton pregnancies dur-
ing miscarriage when compared with singleton pregnan-
cies which did not result in miscarriage (MoMkisspeptin:
1.08  0.47, singleton-no-miscarriage, 0.69  1.35, sin-
gleton-with-miscarriage, P  .001 vs. singleton-no-mis-
carriage) (Figure 2B). Receiver operator characteristic
(ROC) curve analysis suggested that kisspeptin had a
higher diagnostic performancewith respect tomiscarriage
when compared with hCG (ROC area under curve:
0.899 0.025, kisspeptin; 0.775 0.040, hCG, P .01
vs. kisspeptin) (Figure 2C-D). A kisspeptin threshold of
1630 pmol/L had 86% sensitivity (95% CI: 73%–94%)
and 70% specificity (95% CI: 67%–73%) for detecting
miscarriage, and a kisspeptin threshold of 1463 pmol/L
had an 80% (95% CI: 66%–90%) sensitivity and a 75%
(95%CI: 72%–78%) specificity for miscarriage. Patients
with kisspeptin  1630 pmol/L had a 13.8% chance of
miscarriage being subsequently diagnosed (ie, 13.8%pos-
itive predictive value (PPV)), whereas patients with kiss-
Figure 1. Plasma kisspeptin and serum hCG have distinct distributions when classified by gestation in women with
singleton pregnancy who did not miscarry. A-B: In singleton pregnancy not resulting in miscarriage, mean plasma levels of kisspeptin
during the antenatal booking visit increased progressively with increasing gestation (A), and correlated significantly with gestational age (B). C-D:
In singleton pregnancy not resulting in miscarriage, mean serum hCG during the antenatal booking visit peaked around 8weeks gestation, and
then decreased progressively with increasing gestation (C). Scatter plot of serum hCG vs gestational age is shown with a coarse Lowess Plot
(dotted line) denoting the overall trend in their relationship (D). Data are mean  s.d. *** P  .0001.
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peptin 1630 pmol/L had a 1.0% chance of miscarriage
being subsequently diagnosed (ie, 99.0% negative predic-
tive value (NPV)).
Kisspeptin increased to a significantly lesser extentwith
gestational age, in the cohort of women who experienced
miscarriage when compared with the cohort of women
with uncomplicated pregnancy (slope coefficient for in-
crease in plasma kisspeptin [pmol/L/wk]: 305  15, sin-
gleton-without-miscarriage; 94 30, singleton-with-mis-
carriage; F  25.2, DFn  1, DFd  945, P  .0001)
(Figure3A).Logistic regressionanal-
ysis was performed to investigate
whether the relationship between
kisspeptin andmiscarriagewas inde-
pendent of known confounders (Ta-
ble 2). The unadjusted model re-
vealed that the odds of experiencing
a miscarriage decreased by 89%
(OR  0.11; 95% CI: 0.07–0.17;
P .0001) for each 10-fold increase
in kisspeptin. After adjustment for
subject age, gestation, smoking, BP,
and BMI, the odds of experiencing
miscarriage decreased by 87%
(OR  0.13; 95% CI: 0.08–0.22;
P .0001) for each 10-fold increase
in kisspeptin.
Combined testing of kisspeptin
with hCG
Logistic regression analysis was
performed to explore if the diagnos-
tic accuracy of using combined kiss-
peptin and hCG levels was superior
to kisspeptin alone. Combined kiss-
peptin and hCG measurement
(OR 0.10; 95%CI: 0.06–0.17; P .0001) had similar
diagnostic accuracy when comparedwith kisspeptinmea-
surement alone (OR  0.11; 95% CI: 0.07–0.17; P 
.0001).
Relationship of plasma kisspeptin with time to
diagnosis of miscarriage
Ultrasonography confirmed fetal viability in 13/50
pregnancies who later miscarried, an average of 348 
Figure 2. Plasma kisspeptin and serum hCG as markers of miscarriage in
asymptomatic women during singleton pregnancy A,B: Multiples of median (MoM)
levels of plasma kisspeptin (A) and serum hCG (B) were calculated to correct for gestational age
at the time of blood collection in asymptomatic women attending their antenatal booking visit
for a singleton pregnancy. Levels of each hormone are presented in asymptomatic women who
were and were not later diagnosed with miscarriage. C,D: Receiver Operator Characteristic
(ROC) analysis of diagnostic performances of plasma kisspeptin (C) and serum hCG with respect
to miscarriage. Data are mean  s.d.*** P  .0001.
Table 2. Logistic regression model for miscarriage risk in relation to plasma kisspeptin in women during the
antenatal booking visit. The unadjusted odds of experiencing a miscarriage decrease by 89% (OR  0.11; 95% CI:
0.07 to 0.17; P  0.0001) for each unit increase in (Log) plasma kisspeptin. After adjusting the model by age,
gestational age (weeks) and BMI; we found that the effects of kisspeptin changes slightly. After adjustment for
confounders, the odds of experiencing a miscarriage still decrease by 87% (OR  0.13; 95% CI: 0.08 to 0.22; P 
0.0001) for each unit increase in (Log) kisspeptin
Parameter
Unadjusted Adjusted
Model 1 Model 2 Model 3
(Log) Kisspeptin 011 (0.07, 0.17)
P  0.0001
0.14 (0.08, 0.22) P
 0.0001
0.13 (0.08, 0.22) P
 0.0001
Age 1.02 (094,
111) P 
0.627
1.03 (0.94, 1.12) P
 0.565
BMI 0.96 (0.88, 1.05) P 
0.406
0.97 (0.89, 1.07) P
 0.559
Gestation age 0.72 (0.55, 0.95) P 
0.019
0.68 (0.51, 0.91) P
 0.010
Smoking 1.31 (0.24, 7.23) P 
0.755
1.23 (0.22, 6.78) P
 0.811
Diastolic Blood
Presure
0.99 (0.93, 1.05) P
 0.649
Systolic Blood
Pressure
0.99 (0.96, 1.03) P
 0.771
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6.8days (range 2–85days) following kisspeptin measure-
ment. We investigated in more detail the length of time
following kisspeptin and hCG measurement, when pa-
tients were diagnosed with miscarriage (Figure 3).
Kisspeptin. Compared with unaffected pregnancies, kiss-
peptinwas significantly lower inwomenwho experienced
miscarriage when compared with unaffected pregnancies;
lowest levelswere observed in patientsmiscarrying during
the first week following bloodmeasurement (kisspeptin in
pmol/L: 2250 1045 no miscarriage; 195 116 miscar-
riage 7days, P .001 vs. no miscarriage). Intermediate
values were obtained in patients miscarrying between 7 to
21days following the blood test (kisspeptin in pmol/L:
709  750 miscarriage 7–21days; P  .001 vs. no mis-
carriage andP .001vs.miscarriage7days).Kisspeptin
levels in women miscarrying  21days following the
blood test were higher than the other miscarriage groups
but significantly lower than the group that did not mis-
carry (kisspeptin in pmol/L: 951  716 miscarriage 
21days, P  .001 vs. no miscarriage) (Figure 3A). There
was a significant correlation between kisspeptin and the
time following blood measurement that miscarriage was
diagnosed (r20.23, P  .001) (Figure 3B).
hCG. This was only lower in women who experienced
miscarriagewhen comparedwith unaffected pregnancy, if
blood measurement was within 3weeks prior to the diag-
nosis of miscarriage (hCG in IU/Lx1000: 85.1 39.3, no
miscarriage; 17.2 21.6miscarriage 7days,P .05 vs.
no miscarriage; 51.8  55.6 miscarriage 7–21days, P 
.05 vs. nomiscarriage; 63.8 37.0miscarriage 21days,
Pns vs.7days) (Figure 3C). hCG did not correlate sig-
nificantlywith the time followingbloodmeasurement that
miscarriagewas diagnosed (r20.028, Pns) (Figure 3D).
Relationship between plasma kisspeptin and
miscarriage in multiple pregnancies
Thirty-two of the subjects had multiple pregnancies.
We therefore investigated whether and how the observed
relationship between kisspeptin and viability of preg-
nancy, might also apply to multiple pregnancies. MoM
kisspeptinwas significantly higher in twinpregnancies un-
affected by miscarriage when compared with single preg-
nancies unaffected by miscarriage (MoM kisspeptin:
1.060.42, singleton-no-miscarriage, 1.640.54, twin-
no-miscarriage, P  .001 vs. singleton-no-miscarriage;
2.09 0.26, triplet-no-miscarriage,P .05 vs. singleton-
no-miscarriage) (data not shown). In pregnancies uncom-
plicated by miscarriage, MoM hCG was significantly
higher in twin pregnancy, but not triplet pregnancy when
compared with single pregnancy (MoM hCG: 1.08 
0.47, singleton-no-miscarriage, 1.70  0.49, twin-no-
miscarriage, P  .001 vs. singleton-no-miscarriage;
1.88  0.27, triplet-no-miscarriage, Pns vs. twin-no-
miscarriage) (data not shown). Ten of the thirty twin preg-
nancies and neither of the triplet pregnancies resulted in
death of a single fetus. Death of a single fetus during twin
pregnancy significantly reduced MoM kisspeptin and
MoMhCG to levels comparable with successful singleton
pregnancy (MoM kisspeptin: 1.06  0.42, singleton-no-
miscarriage; 1.15  0.58, twin pregnancy with miscar-
riage of one fetus, Pns vs. singleton-no-miscarriage)
(MoM hCG: 1.08  0.47, singleton-no-miscarriage;
1.23 0.84, Pns vs. singleton-no-miscarriage) (data not
shown).
Discussion
Miscarriage is a tragic event, occurring most often before
the sixthweek of gestation due to nonviable chromosomal
defects (8). Miscarriages after the sixth week of gestation
are less common, but are more strongly associated with
identifiable pathologies such as intrauterine infection and
autoimmune disorders. It is therefore important to inves-
tigate whether simple and safe tests can be developed to
identify pregnancies at high risk of miscarriage; as this
could improve thequalityof informationgiven topatients,
facilitate enhanced or targeted obstetric surveillance, and
potentially improve obstetric outcomes. Kisspeptin has
been recently identified as a hormone essential for fertility,
pubertal development, and an important regulator of pla-
cental invasion. We report the results of the first large
study of plasma kisspeptin levels at the booking antenatal
visit. Our data suggest for the first time that plasma kiss-
peptinat antenatal bookingvisit is dramatically reduced in
asymptomatic women  6weeks gestation who later ex-
perience miscarriage when compared with unaffected
pregnancies.
A rising level of serum hCG measured during multiple
hospital visits is currently used to assess fetal viability dur-
ing early pregnancy (26). However, this approach is only
valid if performed before the eighth gestational week,
when serum hCG levels are still rising, as our data and
previous reports demonstrate (27). Furthermore, serum
hCG is in general not used as a biomarker for pregnancy
viability beyond the first trimester of pregnancy (28). Our
data indicates that a single measurement of either serum
hCG or kisspeptin 6weeks gestation helps discriminate
between viable and nonviable pregnancies, but plasma
kisspeptin had superior diagnostic performance. In sin-
gleton pregnancies, a first trimester kisspeptin level of 
1463 pmol/L had an 80% (95% CI: 66%–90%) sensitiv-
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ity and a 75% (95% CI: 72%–78%) specificity for mis-
carriage, andakisspeptin level of1630pmol/Lhad86%
sensitivity (95%CI73%–94%)and70%specificity (95%
CI 67%–73%) for detecting miscarriage. In comparison,
a first trimester hCG level of 61440 IUhad a 72% (95%
CI: 57.5%–84%) sensitivity and 71% (95% CI: 68%–
74%) specificity formiscarriage. Combining the hCGand
kisspeptin measurements as a predictive test for viability
did not greatly improve the diagnostic accuracy achieved
using kisspeptin alone, indicating that perturbation of
kisspeptin secretion in our cohort of women ranging from
6–29weeks gestationwasmore frequently associatedwith
miscarriage than changes in serum hCG concentration.
Thismaybebecausedefects inhCGsecretionor regulation
in pregnancy are more important earlier in fetal develop-
ment, such as at implantation, while kisspeptin related
defects may appear later in gestation.
Kisspeptin was originally termed metastin (14), owing
to its original description as a regulator of tumor metas-
tasis and invasion into surrounding tissue. In keepingwith
this role, KISS1 is expressed abundantly within the syn-
cytiotrophoblast cells of the placenta as it invades into the
uterine wall. It is therefore possible that kisspeptin regu-
lates placental invasion, andmay represent a novelmarker
of placental function. Expression of kisspeptin is reduced
inplacental tissue frommiscarriedpregnancieswhen com-
pared with gestation-matched pregnancies (21). Further-
more, case-control studies have reported that reduced
plasma kisspeptin levels are ob-
served in women with preeclampsia
when comparedwith uncomplicated
pregnancies (29). Circulating kiss-
peptin levels have been reported to
be lower in women with threatened
miscarriage (pain or bleeding during
pregnancy) when compared with
women with uncomplicated preg-
nancy (30). However these data are
difficult to interpret since no correc-
tion was made for gestation, which
was lower in the miscarriage cases
when compared with cases without
miscarriage.
Using logistic regression we ob-
served that plasma kisspeptin defi-
ciency remains highly associated
with miscarriage, even after correc-
tion for gestation and other clinical
factors at the time of plasmakisspep-
tin measurement. Plasma kisspeptin
was measured in the women in the
cohort with multiple pregnancies
during their booking antenatal visit.
Mean plasma kisspeptin level was higher in twin pregnan-
cies and highest in triplet pregnancies.However, the death
of a single fetus in a twin pregnancy was associated with
a mean plasma kisspeptin level that was comparable to
levels measured in viable singleton pregnancies. Taken to-
gether these findings suggest that circulating kisspeptin
levels are derived solely from functioning placental tissue
anddirectly reflect viable placental tissue volume. In keep-
ingwith this the high plasmakisspeptin levels during preg-
nancy fall to low nonpregnant levels within days of deliv-
ery of the baby and passing of the placenta (18). These
observations are also in keeping with the excellent per-
formance of kisspeptin as a biomarker for miscarriage in
women  6weeks gestation in our study.
Our observation that the slope-coefficient for correla-
tion of kisspeptin levels with time of gestation across the
cohort of women who experienced miscarriage was sig-
nificantly lower than for those who had an unaffected
pregnancy, suggests that a higher rate of increase in cir-
culating plasma kisspeptin would be expected in a viable
as compared with a failing pregnancy. It would be inter-
esting therefore to examine this directly in a further study
in which serial measurements of kisspeptin in individual
patients would be collected. The serial measurements
could then be used to derive kinetic parameters that could
further enhance the diagnostic performance of kisspeptin
measurement for assessment of fetal viability. Another
Figure 3. Time elapsed following measurement of plasma kisspeptin or serum
hCG, to diagnosis of miscarriage A: Plasma kisspeptin is significantly lower in
pregnancies during miscarriage, regardless of the time elapsed between the blood test and
diagnosis of miscarriage. B: Levels of plasma kisspeptin correlated with time elapsed until
diagnosis of miscarriage, in asymptomatic singleton pregnancy. C: Serum hCG is only lower in
pregnancies during miscarriage, if the time elapsed between the blood test and diagnosis of
miscarriage is  21days. D: Scatterplot of serum hCG vs time elapsed until diagnosis of
miscarriage, during asymptomatic singleton pregnancy. *, P  .05; ***, P  .001.
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possibility would be to compare absolute and kinetic pa-
rameters for both hCG and kisspeptin measurement to
determine optimal sampling times and an optimal com-
bination to maximize discrimination.
In our study women were recruited at their routine an-
tenatal booking visit, therefore blood samples were not
collected during the earliest stages of pregnancy (ie,
6weeks gestation). Further studies are needed to deter-
mine if the high observed performance of kisspeptin to
detect miscarriage remains true during earlier gestation. It
is reassuring that follow-up data was available on fetal
viability in the vastmajority (ie, 99%) of subjects included
in our study; however we excluded 12 patients that were
lost to follow-up who may (or may not) have suffered
miscarriage. This study was carried out in a tertiary ob-
stetric center that provides care for women with low and
high-risk pregnancies as well as pregnancies that resulted
fromnatural and assisted conception, therefore the results
may be generalized to similar populations of pregnant
women. During the current study, samples were stored at
–20°Cbetween 10 and31months prior to kisspeptinmea-
surement. We therefore examined whether levels of
plasma kisspeptin were related to the duration of storage.
There was no significant difference between MoM kiss-
peptin levels among samples stored for 10, 27, 28, 29, 30
and 31months in patients with singleton pregnancies that
did not miscarry. Our data therefore suggest that the du-
rationof sample storagedidnot significantly affect plasma
kisspeptin levels.
In summary, we have performed the largest study to
date, prospectively determining levels of plasma kisspep-
tin in a large cohort of pregnant women attending their
antenatal booking visit.Ourdata suggest that plasmakiss-
peptin measurement in asymptomatic women  6weeks
gestation at antenatal booking visit, either alone or in
combination with hCG, may be associated with miscar-
riage risk.
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